1. Volume 63, Issue 6, Pages 2262-2268 (June 2003)
Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection 
Akihiko Kato, Mari Odamaki, Hajime Nakamura, Junji Yodoi, Akira Hishida 
Kidney International 
Volume 63, Issue 6, Pages (June 2003)
DOI: /j t x
Copyright © 2003 International Society of Nephrology Terms and Conditions

2. Figure 1
Serum thioredoxin (TRX) in hemodialysis (HD) patients. A significant increase in blood TRX is present in HD patients without hepatitis C virus (HCV) infection compared to normal subjects. TRX was increased to a greater extent in patients with HCV infection than those without HCV infection.
Kidney International  , DOI: ( /j t x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

3. Figure 2
Blood thioredoxin (TRX) and serum asparate aminotransferase (AST) in dialysis patients with (A) and without (B) hepatitis C viremia (HCV). TRX was significantly and positively correlated with AST, both in patients with (N = 59) and without hepatitis C virus infection (N = 85).
Kidney International  , DOI: ( /j t x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

4. Figure 3
Blood ferritin and oxidative stress markers in hepatitis C virus (HCV)-infected dialysis patients. Serum ferritin was significantly and positively associated with thioredoxin (TRX) and malondialdehyde (MDA) in patients with chronic HCV infection (N = 89).
Kidney International  , DOI: ( /j t x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

5. Figure 4
Iron injection and blood thioredoxin (TRX) in hemodialysis patients. Hemodialysis patients receiving weekly iron injection (40 mg, intravenously) have a higher TRX level compared to those without iron supplement, both in patients with and without hepatitis C virus (HCV) infection.
Kidney International  , DOI: ( /j t x)
Copyright © 2003 International Society of Nephrology Terms and Conditions